EP0440606A1 - Macrocyclic chelating agents and chelates thereof - Google Patents

Macrocyclic chelating agents and chelates thereof

Info

Publication number
EP0440606A1
EP0440606A1 EP89900817A EP89900817A EP0440606A1 EP 0440606 A1 EP0440606 A1 EP 0440606A1 EP 89900817 A EP89900817 A EP 89900817A EP 89900817 A EP89900817 A EP 89900817A EP 0440606 A1 EP0440606 A1 EP 0440606A1
Authority
EP
European Patent Office
Prior art keywords
tetraaza
carboxymethyl
benzyloxy
hydroxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP89900817A
Other languages
German (de)
English (en)
French (fr)
Inventor
Ernst Felder
Carlo Musu
Luciano Fumagalli
Fulvio Uggeri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco SpA
Original Assignee
Bracco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco SpA filed Critical Bracco SpA
Publication of EP0440606A1 publication Critical patent/EP0440606A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Definitions

  • the present invention relates to novel macrocyclic chela ⁇ ting agents deriving from 1, , 7,10-tetraazacyclododecane of general formula I ⁇
  • A is a group of formula
  • R is H or a C -C straight or branched alkyl group, or a benzyl group which can be mono- or poly-substituted on the aromatic ring by halogen, hydroxy, carboxy, carbamoyl, alkoxycarbonyl, sulphamoyl, lower alkyl, lower hydroxyalkyl, amino, acylamino, acyl, hydroxyacyl groups, or a group of formula H(OCH CH ) -,
  • X is a O-R group in which R.. is H or a C -C_ alkyl, 1 1 5 hydroxyalkyl, alkoxyalkyl, alkoxyhydroxyalkyl group, or a polyoxaalkyl group having 1 to 15 oxygen atoms and 3 to 45 carbon atoms, or X is a -NR R group in which R and R , which can be the same or different, are C -C 3 1 6 alkyl, hydroxyalkyl, alkoxyalkyl or alkoxyhydroxyalkyl groups having up to 5 hydroxy groups and
  • B , B and B which can be the same or different, have the same meaning as A or they are H or a group of formula
  • R is H or a C -C straight or branched alkyl group
  • Y is a O-R group in which R is H or a C -C alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyhydroxyalkyl group, or a polyoxaalkyl group having 1 to 15 oxygen atoms and 3 to 45 carbon atoms, or Y is a-NR R group in which R
  • R which can be the same or different, are H or
  • the present invention also relates to the preparation of compounds of general formula I and of the complex salts thereof, to their uses and, when indicated, to the pharma- ceutical and diagnostic compositions thereof.
  • the chelating compounds of the present invention and the complex salts thereof can have a wide range of applica ⁇ tions.
  • No limiting examples of use of said chelating agents are jthe recovery, separation, selective extraction of metal ions even at very low concentrations, their therapeutical use as detoxifying agents in cases of inadvertent bodily incorporation of metals or radioiso- topes, their use as ion carriers, or the other ones appa ⁇ rent to those skilled in the art.
  • the chelat- ing agents may be used directly or often they have been bonded covalently or non-covalently to macromolecules or insoluble surfaces or have been otherwise incorporated into structures that can carry them to specific sites.
  • the complex salts of the chelating agents of formula I with the metal ions of the elements with atomic numbers of 20 to 31, 39, 42, 43, 44, 49 or 57 to 83 and, optionally, salified by physiologically biocompatible ions of organic or inorganic acids or organic or inorganic bases or aminoacids are surprisingly suitable for use as contrast agents in medical diagnosis in nuclear medicine and in N.M.R., E.S.R., X-ray and/or ultrasonic diagnosis.
  • Said derivatives for the purpose of optimal diagnostic use, can also be bound or incorporated covalently or non-covalently into biomolecules, .macromolecules or mole- cular aggregates characterized in that they can selective- ly concentrate in the organ or in the tissue under examination.
  • radioisotopes as internal tracers in the organism should be mentioned.
  • One of the biggest problems connected with the use of radioisotopes is their selectivity of distribution, while another important aspect is their excretion in an accepta- ble time.
  • Another imaging technique concerns with the use of ultrasounds to measure the difference in the reflections at the interfaces between tissues of different density.
  • the administration of a suitable amount of a dense non-radioactive element or metal ion can give such a dif ⁇ ference in reflectivity that can emphasize even small otherwise non detectable lesions.
  • a third diagnostic technique uses nuclear magnetic reso ⁇ nance to create internal images of the human body.
  • the development of contrast agents is of particular importance for the following reasons: a) to improve the specificity of the diagnosis, b) to identify at an earlier stage small lesions, c) to more precisely define the extension of a tumoral mass, d) to improve the signal to noise ratio and to shorten the time of acquisition of the images, allowing also better use of the instruments, e) to increase the contrast between those contiguous areas (for instance abdominal or pelvic) where it is parti- cularly difficult to obtain well defined images, f) to obtain good informations on blood flow and on tissue perfusion.
  • contrast media containing paramagnetic complex salts of lanthanides and transition metals have already been claimed for instance in EP 71564 and in US-Pat. 4,639,365, and in patent appli ⁇ cations DE 3401052, EP-A 135125, EP-A 130934, DE 3324236, EP-A 124766, EP-A 165728, WO 87/02893, EP-A 230893.
  • contrast agents for N.M.R. present some problems as far as regards their capa ⁇ city of influencing the relaxation time of the atomic nuclei involved, their often insufficient selectivity in bonding the metal ion, their stability, their selectivity for the organ under' examination, or their biological tole ⁇ rability.
  • Gd-DTPA/N-Methyl-D-glucamine is too quickly removed from the blood stream and from the lesions of the tissues under examination. This reduces the time available for obtaining images significant from diagnostic point of view. Moreover the diffusion of the contrast agent between the, healthy part and the diseased one is often so fast that the contrast between the two regions can be too weak. To overcome these difficulties, the problem has been ap ⁇ proached in many ways among which the most interesting are: a) Other chelating agents have been studied, in particular macrocyclic ones, of which the most effective proved to be 1,4,7,10-tetraazacyclododecane-N,N' ,N",N" '-tetra- acetic acid (DOTA).
  • DOTA 1,4,7,10-tetraazacyclododecane-N,N' ,N",N" '-tetra- acetic acid
  • Gadolinium and its chelating agents have been che ⁇ mically-conjugated to macromolecules such as, for in ⁇ stance, proteins (albumin, etc.), immunoglobulins, or to cellulose or other polymeric matrices.
  • macromolecules such as, for in ⁇ stance, proteins (albumin, etc.), immunoglobulins, or to cellulose or other polymeric matrices.
  • this generally improved the relaxivity of Gd, but on the other hand it was necessarily accompanied by a sub-optimal dosage, because of limitations in solubili ⁇ ty, toxicity and the substitution density of the macro ⁇ molecules.
  • the chelating agents of formula I have shown an excellent scavenging capacity for metal ions even in very diluted solutions. A significant example of said property is the
  • soluble and the poorly soluble compounds are suitable for oral or enteral administration, and therefore of particular usefulness for visualization of the gastrointestinal tract.
  • parenteral administration they are preferably formulated as a sterile aqueous suspension or solution, whose pH can range for instance from 6.0 to 8.5. Said sterile aqueous suspensions or solutions can be administered in concentrations varying from 0.002 to 1.0 molar.
  • Said formulations can also be lyophilized and supplied as such, to be reconstituted at the moment of their use.
  • said agents can be formulated as a suspension or a solution containing additives suitable for instance to increase viscosity.
  • chela ⁇ ted metal ions For oral administration they can be formulated according to preparation methods commonly used in pharmaceutical technology, optionally also as a coated formulation so as to have additional protection against the acid pH of the stomach, preventing in that way the release of the chela ⁇ ted metal ions which takes place in particular at the pH values typical of gastric juices.
  • Other excipients such as sweetening or flavouring agents, can be added according to known pharmaceutical formulation techniques.
  • Suspensions or solutions of complex salts can also be formulated as aerosols to be used in aerosol-bronchogra- phy.
  • Some of the complex compounds of the invention have a surprising organ specificity, in that they particularly concentrate in the liver, in the spleen or, after intra- lymphatic, intraparenchymal, intramuscular or subcutaneous application, in the lymphatic vases and in the lymph no- des.
  • the resulting contrast between the organ under examination and adjacent tissues permits improved imaging of said organ by N.M.R.
  • metal complexes of the chelating agents object of the present invention can also be used as contrast agents in nuclear medicine and for electron spin resonance or echographic analyses.
  • the metal central ions in the chelated complexes are, respectively, a radioisotope for
  • A is preferably a ⁇ -hydroxy- ⁇ X-propionic, ⁇ -methoxy-Wrpropionic or ⁇ -benzylo- xy-O-propionic group, optionally esterified or preferably substituted by an amide residue which can be free, mono- or bi-substituted by alkyl, hydroxyalkyl, alkoxyalkyl or alkoxyhydroxyalkyl groups.
  • R can preferably be H or a straight or branched alkyl group, such as a methyl, ethyl, propyl, isopropyl, butyl, isobutyl group or a benzyl or a substituted benzyl group as. defined in formula I.
  • R can also be an acyl or hydroxyacyl group.
  • R can also be a polyoxaethylene group of formula H(OHCH_CH.)_ -, Me(OCH_CH.)_ -, o Et(OCH.CH.)_ -. 2 2 2-4 2 2 2-4 2 2 2-4 2 2-4
  • X can be a hydroxy group or also a-O-R group, wherein R is as defined in formula I.
  • R are the following: methyl, ethyl, isopropyl, 2-hydroxyethyl, 2-hydroxypropyl, 1,3-di- hydroxyisopropyl, polyoxaalkyl groups.
  • X can preferably be also an hydroxyalkylamino group of formula -NR R , in which R and R are as defined in formula I.
  • R and R are as defined in formula I.
  • Non-limiting examples of said groups are the following ones: amino-, 2-hydroxyethylamino-, 2-hydroxypropylamino-,
  • ⁇ ir preferably are an acetic or an ( -propionic group, eventually esterified or substituted by an amido residue which can be in the free form or mono- or bi-substituted by alkyl, hydroxyalkyl, alkoxyalkyl or alkoxyhydroxyalkyl groups.
  • R can preferably be hydrogen or straight or branched lower alkyl, preferably methyl.
  • R are the following: hydrogen, methyl, straight or branched propyl, butyl and pentyl groups, as defined in formula I.
  • Y can preferably be a hydroxy group or a -O-R group, in which R has the above defined meanings of formula I.
  • R_ are the following: methyl,
  • Y can preferably be also a hydroxyalkylamino group of formula -NR R in which R and R have the above mentioned meanings of formula I.
  • Non-limiting examples of said groups are the following ones: amino, 2-hydroxyethylamino-, 2-hydroxypropylamino-, 2,3- dihydroxypropylamino- 1,3-dihydroxyisopropylamino-, 1,3- dihydroxy-2-methyl-isopropylamino-, 2, 3,4-trihydroxy-l-bu- tyla ino-, 1,3,4-trihydroxy-2-butylamino-, 1,3-dihydro- xy-2-hydroxymethyl-isopropylamino-, N-methyl-N-2-hydroxy- ethylamino-, N-methyl-N-2,3-dihydroxypropylamino-, N-me- thyl-N-1,3-dihydroxyisopropylamino-, N-methyl-N-2,3,4,5,6- -pentahydroxyhexylamino-, N-2-hydroxyethyl-N-2,3-dihydro ⁇ xypropylamino-,
  • Metal ions suited to form complex salts with the chelating agents of general formula I are mainly the di- or triva— lent ions of the elements having atomic numbers ranging from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83 and particularly preferred are Fe , Fe , Cu , Cr , perhaps,(3+) _ (3+) n (3+) M (2+) Gd , Eu , Dy or Mn
  • metal radioisotopes particularly preferred are
  • Preferred inorganic acid anions comprise ions such as chlorides, bromides, iodides or other ions such as sulfate.
  • Preferred organic acid anions comprise ions of acids which are generally pharmaceutically used to salify basic substances, such as acetate, succinate, citrate, fumarate, maleate.
  • Preferred inorganic base cations comprise alkali metal ions, such as lithium, potassium and sodium, the latter being particularly preferred.
  • Preferred organic base cations comprise primary, secondary and tertiary amines, such as ethanolamine, diethanolamine, morpholine, glucamine, N,N-dimethylglucamine and N-methyl- glucamine, the latter being preferred.
  • Preferred amino acid cations comprise, for example, those of lysine, arginine and ornithine.
  • Non-limiting examples of the macromolecules suited for conjugation with the chelate complexes of the invention are the following: biomolecules, such as hormones (insu ⁇ lin), prostaglandins, steroidal hormones, amino sugars, peptides, proteins (albumin, human serum albumin), lipids, antibodies such as monoclonal antibodies, polysaccharide chains.
  • biomolecules such as hormones (insu ⁇ lin), prostaglandins, steroidal hormones, amino sugars, peptides, proteins (albumin, human serum albumin), lipids, antibodies such as monoclonal antibodies, polysaccharide chains.
  • the chelated complexes of the invention can also be incorporated into liposomes, used "in form of mono- or multi-lamellar vescicles.
  • the chelating agents of general * formula I and the complex salts thereof are preferably prepared by reacting 1, ,7,10-tetraazacyclododecane (II), prepared according to the method of Atkins et al. (JACS 96, 2268 (1974)),
  • Compound IV can also be obtained, for example, by protect ⁇ ing diethylenetriamine V with a suitable protecting group P, wherein P can be, for example, a phthaloyl group or another appropriate protective group known in the literature (T.W. Greene: "Protective groups in organic synthesis”- 1980),
  • Compound IV or the polysubstituted analogues thereof can in turn be subjected to condensation with the appropriate 0(-halo-acetic derivative VIII, or with a suitable precursor thereof (such as an ester or a nitrile).
  • chelation of the desired metal ion is obtained preferably by reacting the appropriate derivative of for- mula I with the stoichiometric amount of metal, in form of a salt or an oxide, possibly in the presence of the base or acid amounts necessary for neutralization.
  • Condensation of II with III is carried out preferably in water or in a dipolar aprotic organic solvent, such as dimethylformamide (DMF) or dimethylace amide (DMAC) or in a mixture thereof, at a temperature from 30 to 150°C, preferably from 40 to 100°C.
  • a dipolar aprotic organic solvent such as dimethylformamide (DMF) or dimethylace amide (DMAC) or in a mixture thereof, at a temperature from 30 to 150°C, preferably from 40 to 100°C.
  • Subsequent condensation of IV with VIII can be effected in an aqueous medium or in an organic solvent, in the presence of an appropriate inorganic or organic base, such as sodium hydroxide, potassium hydroxide, potassium carbo ⁇ nate or tetrabutylammonium hydroxide (TBAOH), at a pH ranging from 8 to 12, preferably from 9 to 11.
  • an appropriate inorganic or organic base such as sodium hydroxide, potassium hydroxide, potassium carbo ⁇ nate or tetrabutylammonium hydroxide (TBAOH)
  • TSAOH tetrabutylammonium hydroxide
  • the temperature can range from 40 to 100°C , preferably from 50 to 70°C.
  • a suspension of 17.2 g of 1,4,7,10-tetraazacyclodode ⁇ cane (0.1 mol) and of 71 g of sodium 2-chloro-3-ben- zyloxypropionate (0.3 mol) in 70 ml of water was heated to 50°C for 24 h.
  • the resulting solution was diluted to 400 ml with water, dropped into 200 ml of 2N HCl, extracted several times with ethylene chloride and then was evaporated to dryness under vacuum.
  • the crude residue was taken up into 400 ml of water and adsorbed on amberlite IR 120, from which it was eluted by means of 5N sodium hydroxide.
  • EXAMPLE 2 2-/1, 4,7, 10-tetraaza-7-(l-carboxy-2-benzyloxy-ethyl)-cy- clododecane-l-yl7 ⁇ 3-benzyloxypropionic acid.
  • the organic phase was evaporated to dryness and the resi ⁇ due was dissolved in 200 ml of 0.01N HCl and washed with ethyl ether..
  • the pH was adjusted to 6 with 10% sodium hydroxide and the aqueous solution was evaporated to dryness.
  • the crude residue was taken up into 30 ml of water and adsorbed on amberlite IR 120, from which it was eluted with 5N ammonium hydroxide. By concentration of the basic eluate, a residue of 7 g was obtained, which was crystallized from water.
  • the mixture was heated to 50°O for 17 h and .the pH was kept at 10 by further additions of 6N sodium hydroxide.
  • the solution was cooled and applied to amberlite IR 120, from which the product was eluted with 5N ammonium hydroxide.
  • the basic eluate was evaporated to dryness, the resulting crude compound was dissolved in water and the solution was acidified to pH 3 with 5N HCl.
  • the precipitate was filtered and crystallized from water to give the desired compound.
  • D(-)-N-methylglucamine salt of the Gd /2-/I,4, 7,10-te- traaza-4, 7,10-tri(carboxymethyl)-cyclododecane-l-yl7-3-ben- zyloxypr ⁇ pionic acid complex To a suspension of 100 g of 2- ⁇ ,4,7,10-tetraaza-4,7,10- tri(carboxymethyl)-cyclododecane-l- l7 ⁇ 3-benzyloxypropionic acid (0.19 mol), obtained according to the process de ⁇ scribed in example 3, in 150 ml of water 36.6 g of D(-)-N-methylglucamine (0.187 mol) were added.
  • the catalyst was removed by filtration and the aqueous solution was evaporated under vacuum at 50°C. Upon drying the residue to constant weight, the desired debenzylated compound was obtained.
  • A Gd /2-/1,4, 7,10-tetraaza-4,7,10-tri(carboxyme ⁇ thyl)-cyclododecane-l-yl7-3-benzyloxypropionic acid, 15 neutralized with N-methylglucamine.
  • An anhydrous lipidic mixture was prepared, having the following composition: egg phosphatidylcholine 75 mol % and cholesterol 25 mol % using the REV method (F. Szoka et al., (1978), Proc Natl. Acad. Sci. U.S.A. 75,4194).
  • A Gd + /2-/1,4,7,10-tetraaza-4,7,10-tri(carboxy e- thyl)-cyclododecane-l-yl7 ⁇ 3-benzyloxypropionic acid, neu ⁇ tralized with N-methylglucamine.
  • EXAMPLE 14 Preparation of a solution of D(-)-N-methylglucamine salt of Gd / 2-/1,4,7,10-tetraaza-4,7,10-tri(carboxymethyl)- -cyclododecane-l-yl7 ⁇ 3-benzyloxypropionic acid complex. 436.8 g (0.500 mol) of the compound obtained according to the procedure described in example 5 were dissolved in 300 ml of pro iniectione (p.i.) water. The solution volume was taken to 500 ml by addition of water p.i., then the solu ⁇ tion was filtered, put in vials and sterilized.
  • pro iniectione p.i.
  • EXAMPLE 15 Preparation of a solution of D(-)-N-methylglucamine salt of Gd / 2-/1,4,7,l ' O-tetraaza-4,7,10-tri(carboxymethyl)- -cyclododecane-l-yl7 ⁇ 3-hydroxypropionic acid complex. 398.8 g (0.500 mol) of the compound obtained according to the procedure described in example 6, were dissolved in 300 ml of water p.i.. The solution volume was taken to 500 ml by addition of water p.i., then the solution was filtered, put in vials -and sterilized.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
EP89900817A 1987-12-24 1988-12-16 Macrocyclic chelating agents and chelates thereof Pending EP0440606A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT23217/87A IT1224416B (it) 1987-12-24 1987-12-24 Chelanti macrociclici e loro chelati
IT2321787 1987-12-24

Publications (1)

Publication Number Publication Date
EP0440606A1 true EP0440606A1 (en) 1991-08-14

Family

ID=11204998

Family Applications (2)

Application Number Title Priority Date Filing Date
EP89900817A Pending EP0440606A1 (en) 1987-12-24 1988-12-16 Macrocyclic chelating agents and chelates thereof
EP88121087A Expired - Lifetime EP0325762B1 (en) 1987-12-24 1988-12-16 Macrocyclic chelating agents and chelates thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP88121087A Expired - Lifetime EP0325762B1 (en) 1987-12-24 1988-12-16 Macrocyclic chelating agents and chelates thereof

Country Status (14)

Country Link
EP (2) EP0440606A1 (es)
JP (1) JP2744920B2 (es)
KR (1) KR900700467A (es)
AT (1) ATE120191T1 (es)
DE (1) DE3853415T2 (es)
ES (1) ES2070845T3 (es)
IE (1) IE67551B1 (es)
IL (1) IL88762A (es)
IT (1) IT1224416B (es)
MX (1) MX9203262A (es)
NZ (1) NZ227421A (es)
PH (1) PH26255A (es)
WO (1) WO1989005802A1 (es)
ZA (1) ZA889597B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466200B1 (en) * 1987-07-16 1996-04-24 Nycomed Imaging As Aminocarboxylic acids and derivatives thereof
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US6039931A (en) * 1989-06-30 2000-03-21 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US5695739A (en) * 1989-06-30 1997-12-09 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
DE4009119A1 (de) * 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5162109A (en) * 1990-09-13 1992-11-10 Mallinckrodt Medical, Inc. Magnetic resonance imaging agents
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
EP0565930A1 (en) * 1992-03-27 1993-10-20 Nihon Medi-Physics Co., Ltd. Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
US5310535A (en) * 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
EP0588229A3 (en) * 1992-09-12 1994-06-15 Hoechst Ag Macrocyclic chelating agents for the preparation of technetium or rhenium complexes
WO1995001346A1 (en) * 1993-06-30 1995-01-12 Akzo Nobel N.V. Chelating compounds
EP0702677A1 (en) * 1994-04-08 1996-03-27 BRACCO International B.V. Aromatic amide compounds and metal chelates thereof
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
IT1274038B (it) * 1994-07-29 1997-07-14 Bracco Spa Chelanti macrociclici loro chelati e relativi usi in campo diagnostico
US5672335A (en) * 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
DE19507820A1 (de) * 1995-02-21 1996-08-22 Schering Ag Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
IT1291624B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1293777B1 (it) * 1997-07-25 1999-03-10 Bracco Spa Processo per la preparazione di tetraazamacrocicli
IT1293778B1 (it) * 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE19744004C1 (de) * 1997-09-26 1999-07-22 Schering Ag Lipophile Metall-Komplexe für Nekrose und Infarkt-Imaging
US6495118B1 (en) 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
IT1297034B1 (it) 1997-12-30 1999-08-03 Bracco Spa Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
IT1297035B1 (it) 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281474A2 (en) * 1987-02-28 1988-09-07 Sumitomo Electric Industries Limited Process for manufacturing a compound oxide-type superconducting wire
EP0282286A2 (en) * 1987-03-13 1988-09-14 Kabushiki Kaisha Toshiba Superconducting wire and method of manufacturing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
DE3772785D1 (de) * 1986-01-23 1991-10-17 Squibb & Sons Inc 1-substituiertes-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecan und analoga.
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281474A2 (en) * 1987-02-28 1988-09-07 Sumitomo Electric Industries Limited Process for manufacturing a compound oxide-type superconducting wire
EP0282286A2 (en) * 1987-03-13 1988-09-14 Kabushiki Kaisha Toshiba Superconducting wire and method of manufacturing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAPANESE JOURNAL OF APPLIED PHYSICS, vol. 26, no. 10, October 1987, pages 1653-1656, Tokyo, JP; O. KOHNO et al.: "Critical current density of Y-Ba-Cu oxide wires" *

Also Published As

Publication number Publication date
KR900700467A (ko) 1990-08-13
ES2070845T3 (es) 1995-06-16
DE3853415D1 (de) 1995-04-27
IT8723217A0 (it) 1987-12-24
EP0325762B1 (en) 1995-03-22
IL88762A (en) 1995-07-31
JPH03501848A (ja) 1991-04-25
MX9203262A (es) 1992-07-01
ZA889597B (en) 1989-09-27
IT1224416B (it) 1990-10-04
ATE120191T1 (de) 1995-04-15
IE883844L (en) 1989-06-24
WO1989005802A1 (en) 1989-06-29
PH26255A (en) 1992-04-01
IL88762A0 (en) 1989-07-31
NZ227421A (en) 1990-10-26
DE3853415T2 (de) 1995-08-31
JP2744920B2 (ja) 1998-04-28
IE67551B1 (en) 1996-04-17
EP0325762A1 (en) 1989-08-02

Similar Documents

Publication Publication Date Title
EP0325762B1 (en) Macrocyclic chelating agents and chelates thereof
US5132409A (en) Macrocyclic chelating agents and chelates thereof
US5582814A (en) 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
US4647447A (en) Diagnostic media
EP0255471B1 (de) 1,4,7,10-Tetraazacyclododecan-Derivate
US5334371A (en) Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
EP0438206B1 (de) 6-Ring enthaltende makrocyclische Tetraaza-Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US8961927B2 (en) Agents for magnetic imaging method
JPH0665174A (ja) ジエチレントリアミンペンタ酢酸−モノアミド及びその錯体及び錯塩、その製法、これを含有するｎｍｒ−、レントゲン−及び放射線−診断剤並びに放射線−又は射線療法剤及びその薬剤の製法
HU210208B (en) Process for preparing derivatived dtpa-complexes and pharmaceutical compositions and diangnostic compositions containing them
EP3442949B1 (en) Contrast agents
EP3551614B1 (en) Dimeric contrast agents
EP0565930A1 (en) Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
US6254850B1 (en) Metal complexes, suitable for use in diagnosis and therapy
WO2000056723A1 (de) Perfluoralkylamide, ihre herstellung und ihre verwendung in der diagnostik
US20020052354A1 (en) Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
SK85498A3 (en) Cascade polymer complexes, process for producing the same and pharmaceuticals containing the same
KR20030022381A (ko) 극성 라디칼과의 퍼플루오로알킬 함유 착물, 이의 제조방법 및 용도
AU620841B2 (en) Macrocyclic chelating agents and chelates thereof
AU617338B2 (en) Aminopolycarboxylic acids and derivatives thereof
EP0822180B1 (en) Chelating compounds, their chelates with paramagnetic metal ions, their preparation and use
AU637052B2 (en) Macrocyclic polyaza compounds containing 5 or 6 rings, process for producing them and pharmaceutical media containing them
EP1061957B1 (en) Manganese (ii) chelates with high relaxivity in serum
JPH0656802A (ja) テトラアザシクロドデカン誘導体およびその用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19900615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

EL Fr: translation of claims filed
XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 88121087.6/0325762 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 18.11.91.

DET De: translation of patent claims
EL1 Fr: translation or corrected translation of claims filed